Emerging safety signals around bone health and gout New research presented to clinicians has flagged a modest increase in the risk of osteoporosis and gout among people treated with GLP‑1 receptor agonists — the class of medicines that includes widely used drugs for diabetes and weight loss. The…
Continue reading...
Continue reading...